treatment-free remission (tfr) – the safety of stopping treatment in chronic myeloid leukemia (cml)
Published 7 years ago • 3.6K plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
2:54
improving eligibility for treatment-free remission in cml
-
1:37
the importance of improving treatment-free remission in patients with cml
-
4:13
what is the best treatment in the next few years to achieve more treatment-free remission in cml?
-
1:22
unmet needs in cml: increasing treatment-free remission & accessibility to tkis
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
1:18:06
treatment free remission (tfr) and dose reduction in cml – what is right for me?
-
1:29:09
online webinar: treatment free remission (tfr) in chronic myeloid leukaemia (cml)
-
7:07
achieving successful tfr in cml & recommendations for monitoring after treatment discontinuation
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
5:46
living with chronic myeloid leukemia - brown dudley (courage thru cancer)
-
3:06
chanelle thornton - chronic myeloid leukaemia (cml) - spot leukaemia
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:14
updates on the smart stop trial: the potential for a chemo-free regimen in the frontline for dlbcl
-
2:06
moving toward a cure for chl without chemotherapy: results of a clinical trial
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:19
maintaining remission in aml and improving long-term survival in patients who do not receive hsct
-
1:24
considerations for tki choice in frontline and r/r cml
-
6:07
treatment-free remission & toxicities of discontinuing cml therapy
-
3:18
predictors for tfr in cml: response duration, secondary treatment & frontline tki choice
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:02
the challenge of treating bpdcn in a resource-limited setting